Causes for reduced bioavailability include
**Core Concept**
First-pass metabolism is a significant factor influencing bioavailability, particularly for orally administered drugs. This phenomenon occurs when a drug is extensively metabolized by the liver upon its first pass through the hepatic portal system, resulting in reduced systemic availability. Understanding the factors contributing to reduced bioavailability is crucial for optimizing drug therapy.
**Why the Correct Answer is Right**
First-pass metabolism is a major contributor to reduced bioavailability. When a drug is administered orally, it is absorbed into the bloodstream and transported to the liver via the hepatic portal vein. Here, it is subjected to extensive metabolism by cytochrome P450 enzymes, particularly CYP3A4, which significantly reduces its systemic availability. This process is often referred to as the "first-pass effect."
**Why Each Wrong Option is Incorrect**
**Option A:** While gastric pH can affect the absorption of certain drugs, it is not a primary factor contributing to reduced bioavailability.
**Option B:** Molecular size can affect the absorption and distribution of drugs, but it is not a direct cause of reduced bioavailability.
**Option C:** Molecular weight is related to the pharmacokinetics of a drug, but it is not a direct contributor to reduced bioavailability.
**Clinical Pearl / High-Yield Fact**
When considering the bioavailability of a new medication, it is essential to evaluate the potential for first-pass metabolism and consider alternative routes of administration, such as topical or parenteral routes, to overcome this limitation.
**Correct Answer:** D. First-pass metabolism